BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said its leadership will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 5:15 p.m. PT. A live webcast will be available on the company’s Events page and a replay will remain accessible for at least 90 days after the presentation.
This provides investors a scheduled opportunity for management commentary on clinical programs and strategy.
Positive
- None.
Negative
- None.
News Market Reaction – BBOT
In the Dec 17 session, BBOT declined 3.54%, reflecting a moderate negative market reaction. Argus tracked a trough of -13.7% from its starting point during tracking.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Inducement grant | Neutral | -1.9% | Inducement stock options granted under 2025 plan at market exercise price. |
| Dec 10 | Preclinical data | Positive | +2.8% | Late-breaking preclinical data for BBO-10203 showing anti-tumor activity. |
| Nov 18 | Investor conferences | Neutral | -1.8% | Planned presentations at two December healthcare investor conferences. |
| Nov 12 | Earnings update | Neutral | -0.9% | Q3 2025 results and pipeline update with cash runway into 2028. |
| Nov 03 | Conference participation | Neutral | +2.9% | Announcement of participation in Jefferies Global Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent BBOT headlines, including conference participation and corporate updates, have usually led to modest single-digit price moves, with preclinical data drawing the clearest positive reaction.
Over the last two months, BBOT has reported Q3 2025 results, highlighted cash and liquidity of $468.3M as of Sep 30, 2025, and advanced three Phase 1 programs with data expected in 2026. Conference participation has been frequent, including Jefferies and multiple December investor events, generally producing small single-digit price changes. Preclinical data for BBO-10203 on Dec 10, 2025 saw a positive 2.79% reaction, while items like inducement grants and other neutral news have slightly negative or modestly positive moves. Today’s JPM conference announcement fits this pattern of incremental, non-fundamental updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. PT.
A live webcast of the presentation will be accessible on the “Events” page of the BBOT website at https://investors.bbotx.com/news-events/events. A replay of the webcast will be available for at least 90 days following the event.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
